Renovaro (NASDAQ: ENOB)
Renovaro Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Renovaro Company Info
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
News & Analysis
Why Enochian BioSciences Was a Winner on Monday
The company scores an exclusive license for new potential coronavirus treatment technology.
Here's Why Enochian BioSciences Stock Skyrocketed Today
The biotech's experimental treatment for HIV could be a game changer.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.